Rob received his MChem degree at the University of Leeds in 2018. As part of his studies, he spent a year in the pharmaceutical industry working for YProTech (now Apex Molecular) and completed a research project in structure-based drug design within the Fishwick Group. Rob completed his PhD at the same institute in July 2022 through the MRC DiMeN DTP programme, where he developed peptidomimetic inhibitors of key protein-protein interactions of the Aurora A kinase under the supervision of Prof. Richard Bayliss and Prof. Andy Wilson. He joined the Kawamura Group soon after as a Postdoctoral Research Associate, where he investigates lysine demethylases (KDMs) in relation to the chemistry of epigenetics and associated cancers.
Outside the lab, Rob is most likely to be found in the gym or up a mountain somewhere!